Combigan (soln)

Generic: Brimonidine tartrate 0.2% | Timolol maleate 0.5%


Combigan (soln)
GENERIC Brimonidine tartrate 0.2% | Timolol maleate 0.5%
SIZE 5mL, 10mL, 15mL
INDICATIONS Reduction of elevated intraocular pressure (IOP)
MECHANISM OF ACTION Reduce aqueous production and increase outflow
MICROBIOLOGY Relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.
CONTRAINDICATIONS & WARNINGS Contraindicated in patients with Asthma, COPD, sinus bradycardia, AV block, cardiac failure, cardiogenic shock, neonates and infants, hypersensitivity reactions
PEDIATRIC USE Contraindicated under age 2. The safety and effectiveness of COMBIGAN® have been established in the age groups 2 – 16 years of age.
PREGNANCY Pregnancy category C | There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent.